Cisplatin is a well-known anticancer drug used to treat various cancers. However, development of cisplatin resistance has hindered the efficiency of this drug in cancer treatment. Development of chemoresistance is known to involve many signaling pathways. Recent attention has focused on microRNAs (miRNAs) as potentially important upstream regulators in the development of chemoresistance. CD44 is one of the gastric cancer stem cell markers and plays a role in regulating self-renewal, tumor initiation, metastasis and chemoresistance. The purpose of the present study was to examine the mechanism of miRNA-mediated chemoresistance to cisplatin in CD44-positive gastric cancer stem cells. We sorted gastric cancer cells according to level of CD44 expression by FACS and analyzed their miRNA expression profiles by microarray analysis. We found that miR-193a-3p was significantly upregulated in CD44(+) cells compared with CD44(−) cells. Moreover, SRSF2 of miR-193a-3p target gene was downregulated in CD44(+) cells. We studied the modulation of Bcl-X and caspase 9 mRNA splicing by SRSF2 and found that more pro-apoptotic variants of these genes were generated. We also found that downstream anti-apoptotic genes such as Bcl-2 were upregulated, whereas pro-apoptotic genes such as Bax and cytochrome C were downregulated in CD44(+) cells compared to CD44(−) cells. In addition, we found that an elevated level of miR-193a-3p triggered the development of cisplatin resistance in CD44(+) cells. Inhibition of miR-193a-3p in CD44(+) cells increased SRSF2 expression and also altered the levels of multiple apoptotic genes. Furthermore, inhibition of miR-193a-3p reduced cell viability and increased the number of apoptotic cells. Therefore, miR-193a-3p may be implicated in the development of cisplatin resistance through regulation of the mitochondrial apoptosis pathway. miR-193a-3p could be a promising target for cancer therapy in cisplatin-resistant gastric cancer.
| INTRODUC TI ON
To date, chemotherapy has been the primary strategy for cancer treatment. However, chemoresistance is a major obstacle to chemotherapy and is one of the main causes of its failure.
Chemoresistance has been shown to develop by three different mechanisms. These mechanisms include deterioration of watersoluble drugs resulting in reduced drug uptake, changes in cells that affect the cytotoxicity of drugs, such as decreased apoptosis or increased DNA repair action, and increased efflux of hydrophobic drugs by ATP-binding cassette transporters.
1 However, the modulation of chemoresistance is still a topic of investigation and complete understanding of the mechanisms underlying the development of chemoresistance has the potential to be enormously helpful to cancer therapy.
Cisplatin (also known as CDDP), a platinum compound, is one of the most commonly used anticancer drugs. Cisplatin was discovered in the 1840s and has been used to treat various types of cancers. Cisplatin binds and crosslinks DNA, thereby inducing apoptosis. 2 In advanced gastric cancer, combination chemotherapies including cisplatin have been shown to result in improved survival times and response rates. 3, 4 Cisplatin resistance has been thoroughly investigated and many different mechanisms of cisplatin resistance have been proposed (pre-, on-, post-, and offtarget). 5 Apoptosis refers to programmed cell death and is distinct from other types of cell death such as necrosis. Apoptosis can occur through two different pathways, termed the intrinsic and extrinsic pathways. The intrinsic apoptosis pathway is related to mitochondrial permeability and is controlled by Bcl-2 family proteins, which regulate permeabilization of the mitochondrial outer membrane. 6 Reactive oxygen species (ROS) can also create pores in the mitochondrial membrane, triggering apoptosis. 7 In the extrinsic apoptosis pathway, death receptors convey death signals from the cell surface to intracellular mediators of this pathway.
8
Cells undergoing apoptosis show distinct morphological changes.
In particular, apoptotic cells show small DNA fragments composed of compacted nuclear contents. Apoptotic cells also migrate and form apoptotic bodies.
9
MicroRNAs (miRNAs) are 22-nucleotide non-coding RNAs that regulate cellular processes by targeting sequence-specific mRNAs.
Generally, miRNAs inhibit translation by binding to the 3′-3′UTR of their target mRNAs. 10 Several miRNAs have been reported to cause drug resistance or suppress apoptosis. 11 miRNAs regulate chemoresistance by targeting tumor suppressor or drug transporter genes.
12
High expression of microRNA (miR)-221/222 has been shown to confer tamoxifen resistance to breast cancer cells through a mechanism that targets p27. 13, 14 Multidrug resistance in gastric cancer cells has also been shown to be associated with decreased expression of miR-15b and miR-16.
15
CD44 is one of the gastric cancer stem cell markers and is critical in regulating self-renewal, tumor initiation, metastasis and chemoresistance. In addition, CD44 correlates with poor prognosis in various human cancers, including breast, brain, colon, pancreatic, and gastric cancers. 16 In our previous study, we reported upregulated CD44 expression in gastric cancer cells and the miR-106b family was significantly upregulated in CD44-positive cancer cells. 17 Although miRNA regulation has been examined as a cancer stem cell characteristic, the mechanism of the miR-193a-3p-dependent cisplatin resistance response underlying gastric cancer stemness has not been fully studied.
Herein, we evaluated cisplatin resistance in CD44(+) gastric cancer cells and found that upregulation of miR-193a-3p was associated with cisplatin resistance. We analyzed the expression levels of miR-193a-3p target such as SRSF2 and various isoforms of downstream SRSF2 targets, including pro-and anti-apoptotic genes. Furthermore, we examined the mechanisms of apoptosis regulation by miR-193a-3p, we inhibited miR-193a-3p in CD44(+) cells and measured cell viability after cisplatin treatment. We found that miR-193a-3p might have potential as a therapeutic target to treat diseases such as cisplatin-resistant gastric cancer through regulation of the mitochondrial apoptosis pathway. 
| MATERIAL S AND ME THODS

| Cell culture
| Flow cytometry analysis and FACS
| MicroRNA microarray
Total RNA from CD44(+) and CD44(−) MKN45 cells was prepared using TRIzol reagent according to the manufacturer's instructions. for 10 seconds and at 60°C for 60 seconds using an AB7500 realtime PCR system (Applied Biosystems). Each sample was examined in triplicate and the amount of PCR product was normalized with respect to U6 as an internal control.
| Immunohistochemistry assay
| Western blot analysis
After washing with PBS, cells were harvested and resuspended in lysis 
protein were prepared by heating the samples at 95°C after the addition of SDS sample buffer (62.5 mM Tris-Cl [pH 6.8], 2% SDS, 10%
glycerol, β-mercaptoethanol and 0.002% bromophenol blue). Samples were loaded onto 8% SDS-PAGE gels for SRSF2 and 12% SDS-PAGE gels for Bcl-X L , Bax, Bcl-2, cytochrome C, cleaved caspase-3 and 
| Immunofluorescence assay
Cells were seeded on glass coverslips in six-well plates. After an Germany).
| MicroRNA inhibitor transfection
MicroRNA inhibitor was purchased from GenePharma (Applied 
| Annexin V apoptosis detection assay
Cells were transfected with a miR-193a-3p inhibitor or a negative control and incubated for 24 hours. Cells were then treated with or without cisplatin (3 μg/mL) and subsequently stained using the Annexin V-FITC Apoptosis Detection Kit I (BD Biosciences) according to the manufacturer's instructions. Samples were analyzed by flow cytometry using the LSR II Flow Cytometer (BD Biosciences).
Each experiment was independently carried out three times.
| MTS assay
Cells were seeded into 96-well plates, incubated overnight and then treated with cisplatin (2 or 2.5 μg/mL). 
| Luciferase assay
The miR-193a-3p seed sequences ( 
| Nuclear morphology
Cells were seeded on glass coverslips in six-well plates. The miR193a-3p inhibitor or negative control was transfected into the cells. After 24 hours, cells were treated with 3 μg/mL cisplatin for 48 hours. Cells were fixed in 4% formaldehyde for 10 minutes and permeabilized in 0.1% Triton X-100 in PBS for 3 minutes. The slides were mounted with DAPI and observed under a fluorescence microscope.
| Statistical analysis
All experiments were done more than three times. All bars are expressed as means ± standard deviations. Two-tailed Student's t test was used for statistical analysis. A statistical difference, represented as an asterisk (*) was considered significant when P < .05. cells ( Figure 1D ).
| RE SULTS
| SRSF2, a miR-193a-3p target gene, is downregulated in CD44(+) MKN45 cells
Next, we investigated the candidate targets of miR-193a-3p such as SRSF2, E2F1, E2F6, MCL1 and PCNA (TargetScan and miRNA.
org website). 18 We conducted real-time PCR to evaluate the expression levels of these candidates and found that SRSF2 and 
| SRSF2 regulates apoptosis-related genes
SRSF2 is known to regulate the alternative splicing of Bcl-X and caspase 9 in favor of pro-apoptotic splice variants. 20 In order to confirm this function of SRSF2 in our system, we evaluated mRNA and protein expression level of Bcl-X L (an anti-apoptotic variant of Bcl-X) and caspase 9a (a pro-apoptotic variant of caspase 9). Bcl-X L was upregulated in CD44(+) cells, whereas caspase 9a was downregulated in CD44(+) cells. We also examined the expression of mitochondrial apoptosis-related genes on both mRNA and protein levels. Bax and cytochrome C such as pro-apoptotic genes were downregulated, whereas an anti-apoptotic gene, such as Bcl-2, was upregulated in CD44(+) cells. Caspase 3 and caspase 9 are known to undergo cleavage during apoptosis, thereby generating increase in the cleaved forms of these proteins. We found that levels of cleaved caspase 3 and caspase 9 were both decreased in CD44(+) cells (Figure 3 ).
| CD44(+) cells induce cisplatin resistance compared with CD44(−) cells
We conducted MTS assays to examine the proliferative capaci- 
| Inhibition of miR-193a-3p increases SRSF2 expression in CD44(+) cells
To study changes in CD44(+) cells resulting from the expression of miR-193a-3p, we transfected miR-193a-3p inhibitor into CD44(+) cells. At 48 hours post-transfection, we carried out real-time PCR to determine the expression level of miR-193a-3p in CD44(+) cells transfected with a negative control or the miR-193a-3p inhibitor.
We found that miR-193a-3p expression was effectively downregulated by its inhibitor ( Figure 5A ). Moreover, we observed that SRSF2 of the miR-193a-3p target increased mRNA expression after downregulation of miR-193a-3p ( Figure 5B ). Protein level of SRSF2 was also examined by western blot analysis of cell lysates and by immunofluorescence assays. By both of these techniques, the level of SRSF2 increased upon inhibition of miR-193a-3p in CD44(+) cells ( Figure 5C,D) . Also, the luciferase activity of SRSF2 was greater in CD44(+) cells transfected with the miR-193a-3p inhibitor than in a negative control ( Figure 5E ).
| Inhibition of miR-193a-3p activates the mitochondrial apoptotic signaling pathway
We next examined mRNA expression levels of SRSF2 targets such 
| Inhibition of miR-193a-3p sensitizes CD44(+) cells to cisplatin
We determined the viabilities of negative control-transfected 
| D ISCUSS I ON
Although gastric cancer incidence is now declining, gastric cancer mortality is still significantly high. Surgical and systemic treatment as well as screening, early detection, and treatment strategies for
Helicobacter pylori infection for gastric cancer are still major health burdens worldwide. 21 Cisplatin is commonly used for adjuvant chemotherapy in advanced-stage gastric cancer patients. Cisplatin has been characterized as a DNA linkage agent, and the cytotoxicity of cisplatin has generally contributed to the ability to form intra-strand and inter-strand DNA linkage. 22 Cisplatin may cause mitochondrial alterations leading to activation of apoptosis or cell death and also oxidative/reticular stress. In many different aspects, cisplatin resistance has been proposed (pre-, on-, post-, and off-target). In the pretarget aspect, several transporters were identified as associated with cisplatin resistance, such as copper transporter 1 (CTR1), coppertransporting ATPase (ATP7B), multidrug resistance-associated protein 2 (MRP2), and volume-regulated anion channels (VRAC).
On-target resistance includes excision repair cross-complementing rodent repair deficiency and complementation group 1 (ERCC1).
Also, bcl-2 family members and the akt pathway are implicated in the post-and off-target mechanisms in cisplatin resistance.
5
CD44 is well known as a proven gastric cancer stem cell marker and known to play a critical role in regulating self-renewal, tumor However, the mechanism of miR-193a-3p-dependent cisplatin resistance response underlying gastric cancer stemness has not been fully elucidated.
In the present study, we first investigated known targets of miR193a-3p and the signaling pathways regulated by these targets. Using real-time PCR analysis, we found that the expression level of miR193a-3p was inversely correlated with levels of SRSF2 and E2F1. We each of which plays a distinctive role. 27 Bcl-X, one of the most studied genes to undergo alternative splicing is known to occur in two isoforms: Bcl-X L and Bcl-X S . Bcl-X L shows anti-apoptotic effects, whereas
Bcl-X S provokes apoptosis. Caspase 9 was spliced into caspase 9a, an isoform known to exert pro-apoptotic effects. 
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